RxDoctor Payments Data

Vinod Chaubey, MD

Interventional Cardiology · Conway, SCNPI 1851656482

Payments from drug & device makers

$3,084in general payments, 2019–2025

Across 142 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$404
  • Cardiovascular Systems Inc.$401
  • Novartis$371
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$318
  • Pfizer$257
  • Biotronik Inc.$161
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,084 in reported general payments places this provider in the 10th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$113,855
Medicare patients
719
Services billed
2,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$229,364
XareltoRivaroxaban74$58,074
EntrestoSacubitril/Valsartan20$22,931
BrilintaTicagrelor29$21,350
Metoprolol Succinate218$4,073
Rosuvastatin Calcium72$2,152
Atorvastatin Calcium141$1,594
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$1,447
Valsartan29$1,438
Carvedilol96$1,073
Ranolazine ErRanolazine13$1,059
Amlodipine Besylate117$920
Isosorbide Mononitrate ErIsosorbide Mononitrate50$808
ClopidogrelClopidogrel Bisulfate74$754
Metoprolol Tartrate148$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$257$229,364232 claims
Johnson & JohnsonXarelto$42$58,07474 claims
NovartisEntresto$371$22,93120 claims
AstraZenecaBrilinta$120$21,35029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →